| Title |
Phase II clinical trial of second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: AVASIRI trial
|
|---|---|
| Published in |
International Journal of Clinical Oncology, October 2011
|
| DOI | 10.1007/s10147-011-0331-2 |
| Pubmed ID | |
| Authors |
Yosuke Horita, Yasuhide Yamada, Ken Kato, Yoshinori Hirashima, Kouhei Akiyoshi, Kengo Nagashima, Takako Nakajima, Tetsuya Hamaguchi, Yasuhiro Shimada |
| Abstract |
FOLFIRI is a standard chemotherapy regimen for the treatment of metastatic colorectal cancer. Although some studies have shown its efficacy in combination with bevacizumab as first-line chemotherapy, there are no data to support FOLFIRI plus bevacizumab as second-line chemotherapy in patients with this form of cancer. The aim of this study was to evaluate the efficacy and safety of FOLFIRI and bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer. |
Mendeley readers
The data shown below were compiled from readership statistics for 45 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 2% |
| Unknown | 44 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 6 | 13% |
| Student > Bachelor | 6 | 13% |
| Researcher | 6 | 13% |
| Student > Master | 5 | 11% |
| Lecturer | 4 | 9% |
| Other | 10 | 22% |
| Unknown | 8 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 23 | 51% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 7% |
| Psychology | 3 | 7% |
| Nursing and Health Professions | 2 | 4% |
| Immunology and Microbiology | 2 | 4% |
| Other | 4 | 9% |
| Unknown | 8 | 18% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 January 2016.
All research outputs
#7,409,591
of 22,655,397 outputs
Outputs from International Journal of Clinical Oncology
#146
of 905 outputs
Outputs of similar age
#46,119
of 136,725 outputs
Outputs of similar age from International Journal of Clinical Oncology
#3
of 7 outputs
Altmetric has tracked 22,655,397 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 905 research outputs from this source. They receive a mean Attention Score of 3.7. This one has gotten more attention than average, scoring higher than 69% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 136,725 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 39th percentile – i.e., 39% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than 4 of them.